CYTK Q2 2022 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$89M+3029.4% YoY

Gross Profit

$32M35.8% margin

Operating Income

-$11M-12.2% margin

Net Income

-$20M-22.3% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+7649.8%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$91M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$772M

Total Liabilities

$660M

Stockholders' Equity

$111M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$89M	$3M	+3029.4%
Gross Profit	$32M	-$34M	+194.8%
Operating Income	-$11M	-$55M	+80.2%
Net Income	-$20M	-$62M	+67.8%

Revenue Segments

Milestone

$1M51%

Research And Development

$968,00049%